This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh, Biontech Rna Pharmaceuticals Gmbh, Biontech Se. Active years: 2020-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 16 
1 out of 19 
1 out of 76 
Years Active: 2020-2022
Title: The Innovative Contributions of Johannes Hendrikus De Graaf
Introduction: Johannes Hendrikus De Graaf, based in Lorzweiler, Germany, is a notable inventor whose work in the field of cancer immunotherapy has led to significant advancements. With two patents to his name, he has made a remarkable impact in the medical community through his innovative approaches to vaccine development.
Latest Patents: De Graaf's most recent patents focus on individualized vaccines for cancer. These inventions relate to the provision of vaccines that are specific to a patient's tumor, which are potentially useful for immunotherapy targeting both primary tumors and tumor metastases. The method outlined in the patent involves identifying cancer-specific somatic mutations in a tumor specimen to create a unique cancer mutation signature for the patient. Following this, a personalized vaccine featuring the identified mutation signature is developed. This innovative approach shows great promise for improving cancer treatment and patient outcomes.
Career Highlights: Throughout his career, De Graaf has contributed to significant research and development in the field of oncology. He has been associated with respected institutions and companies, underscoring his expertise and commitment to cancer research.
Collaborations: De Graaf has worked alongside esteemed colleagues, including Ugur Sahin and Sebastian Kreiter. Their collaboration has fostered advancements in cancer vaccine development, highlighting the importance of teamwork in tackling complex medical challenges.
Conclusion: Johannes Hendrikus De Graaf stands out as a pioneering inventor in the realm of cancer immunotherapy. His innovations and effective collaborations position him as a key contributor to advancements in personalized medicine. As research continues, his work may lead to even greater breakthroughs in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile